David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Comcast
CMCSA
|
+$354M |
| 2 |
Wells Fargo
WFC
|
+$274M |
| 3 |
IBM
IBM
|
+$266M |
| 4 |
Qualcomm
QCOM
|
+$257M |
| 5 |
Mondelez International
MDLZ
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$356M |
| 2 |
PayPal
PYPL
|
+$290M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$261M |
| 4 |
NVIDIA
NVDA
|
+$248M |
| 5 |
AABA
Altaba Inc
AABA
|
+$245M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.31% |
| 2 | Healthcare | 10.66% |
| 3 | Consumer Discretionary | 10.29% |
| 4 | Communication Services | 8.78% |
| 5 | Financials | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1676
CALL
Weibo
WB
$1.73B
| $3.19M | ﹤0.01% |
32,280
+15,120
| +88% | +$1.33M |
|
|
ICPT
1677
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $3.19M | ﹤0.01% |
55,032
+37,691
| +217% | +$4.06M |
|
|
EXTN
1678
DELISTED
Exterran Corporation
EXTN
| $3.18M | ﹤0.01% |
100,714
-14,251
| -12% | -$394K |
|
1679
Fortuna Silver Mines
FSM
$3.67B
| $3.17M | ﹤0.01% |
725,299
-830,079
| -53% | -$3.89M |
|
|
RTN
1680
CALL
DELISTED
Raytheon Company
RTN
| $3.17M | ﹤0.01% |
17,000
| – | – |
|
1681
CALL
Teva Pharmaceuticals
TEVA
$44.2B
| $3.17M | ﹤0.01% |
180,100
+72,500
| +67% | +$1.63M |
|
|
GHDX
1682
DELISTED
Genomic Health, Inc.
GHDX
| $3.17M | ﹤0.01% |
98,773
-6,597
| -6% | -$208K |
|
1683
PUT
Digital Realty Trust
DLR
$71.8B
| $3.16M | ﹤0.01% |
26,700
-4,000
| -13% | -$462K |
|
|
WCG
1684
DELISTED
Wellcare Health Plans, Inc.
WCG
| $3.16M | ﹤0.01% |
18,389
+11,820
| +180% | +$2.07M |
|
1685
Clean Energy Fuels
CLNE
$357M
| $3.16M | ﹤0.01% |
1,272,710
+43,630
| +4% | +$110K |
|
1686
Sysco
SYY
$39.9B
| $3.15M | ﹤0.01% |
58,426
-452,652
| -89% | -$23.6M |
|
1687
PUT
EQT Corp
EQT
$34.3B
| $3.15M | ﹤0.01% |
88,727
| – | – |
|
|
SODA
1688
PUT
DELISTED
SodaStream International Ltd
SODA
| $3.14M | ﹤0.01% |
47,200
-1,700
| -3% | -$99K |
|
1689
ATN International
ATNI
$472M
| $3.13M | ﹤0.01% |
59,489
+42,186
| +244% | +$2.52M |
|
|
JWN
1690
DELISTED
Nordstrom
JWN
| $3.13M | ﹤0.01% |
+66,398
| New | +$3.08M |
|
1691
Teleflex
TFX
$5.88B
| $3.13M | ﹤0.01% |
12,938
-219
| -2% | -$47.6K |
|
|
1692
PUT
Mondelez International
MDLZ
$80.4B
| $3.12M | ﹤0.01% |
76,700
+50,000
| +187% | +$2.12M |
|
1693
Astronics
ATRO
$3.33B
| $3.11M | ﹤0.01% |
144,388
+91,364
| +172% | +$1.87M |
|
1694
MYR Group
MYRG
$4.87B
| $3.11M | ﹤0.01% |
106,757
+21,161
| +25% | +$585K |
|
1695
Theravance Biopharma
TBPH
$884M
| $3.11M | ﹤0.01% |
90,848
-87,859
| -49% | -$2.87M |
|
1696
PUT
Kraft Heinz
KHC
$29.4B
| $3.1M | ﹤0.01% |
40,000
+20,000
| +100% | +$1.67M |
|
1697
Jacobs Solutions
J
$17.7B
| $3.1M | ﹤0.01% |
64,293
+54,593
| +563% | +$2.44M |
|
1698
Kearny Financial
KRNY
$639M
| $3.09M | ﹤0.01% |
201,545
+17,472
| +9% | +$254K |
|
|
WBA
1699
CALL
DELISTED
Walgreens Boots Alliance
WBA
| $3.09M | ﹤0.01% |
40,000
| – | – |
|
1700
Prosperity Bancshares
PB
$8.78B
| $3.08M | ﹤0.01% |
46,939
-128,611
| -73% | -$8.05M |
|
Similar funds
David Shaw's Q3 2017 Portfolio in Review
As of Q3 2017, David Shaw held 3,794 positions worth $65.1B, up 7.7% from $60.5B the previous quarter. Its ten largest holdings account for 9.6% of the portfolio.
David Shaw's Q3 2017 filing shows 469 new, 1,367 increased, 1,237 reduced and 370 closed positions. Its largest new stake was Baker Hughes: 3,076,914 shares worth $113M. The largest sale was Gilead Sciences, an estimated $356M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- David Shaw's largest Q3 2017 buy was Baker Hughes: 3,076,914 shares worth $113M.
- David Shaw added most to Comcast in Q3 2017, an estimated $354M increase.
- David Shaw's biggest Q3 2017 reduction was Gilead Sciences, cutting an estimated $356M.
- David Shaw fully exited Mobileye N.V. in Q3 2017, selling an estimated $72.4M.
- David Shaw's ten largest holdings make up 9.6% of its $65.1B portfolio in Q3 2017.
- David Shaw opened 469 new positions and closed 370 in Q3 2017.
- David Shaw's portfolio value rose 7.7% quarter-over-quarter to $65.1B.
Based on D.E. Shaw & Co's 13F filing for Q3 2017, filed 14 Nov 2017.